IS5888A - Efnameðferð við krabbameini með asetýldínalíni blönduðu gemsítabíni, kapesítabíni eða sisplatíni - Google Patents

Efnameðferð við krabbameini með asetýldínalíni blönduðu gemsítabíni, kapesítabíni eða sisplatíni

Info

Publication number
IS5888A
IS5888A IS5888A IS5888A IS5888A IS 5888 A IS5888 A IS 5888A IS 5888 A IS5888 A IS 5888A IS 5888 A IS5888 A IS 5888A IS 5888 A IS5888 A IS 5888A
Authority
IS
Iceland
Prior art keywords
gemsitabine
capesitabine
acetyldinalin
cisplatin
chemotherapy
Prior art date
Application number
IS5888A
Other languages
English (en)
Inventor
Richard Grove William
Daniel Klohs Wayne
Lynn Merriman Ronald
Original Assignee
Warner-Lambert Company, , Delaware Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company, , Delaware Corporation filed Critical Warner-Lambert Company, , Delaware Corporation
Publication of IS5888A publication Critical patent/IS5888A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
IS5888A 1998-09-25 2001-03-14 Efnameðferð við krabbameini með asetýldínalíni blönduðu gemsítabíni, kapesítabíni eða sisplatíni IS5888A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10180998P 1998-09-25 1998-09-25
PCT/US1999/015386 WO2000018393A1 (en) 1998-09-25 1999-07-08 Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin

Publications (1)

Publication Number Publication Date
IS5888A true IS5888A (is) 2001-03-14

Family

ID=22286531

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5888A IS5888A (is) 1998-09-25 2001-03-14 Efnameðferð við krabbameini með asetýldínalíni blönduðu gemsítabíni, kapesítabíni eða sisplatíni

Country Status (34)

Country Link
US (3) US6469058B1 (is)
EP (1) EP1115391B1 (is)
JP (1) JP2002525320A (is)
KR (1) KR20010075348A (is)
CN (1) CN1319009A (is)
AP (1) AP2001002109A0 (is)
AT (1) ATE225655T1 (is)
AU (1) AU762079B2 (is)
BG (1) BG105470A (is)
BR (1) BR9913952A (is)
CA (1) CA2342981A1 (is)
CZ (1) CZ2001905A3 (is)
DE (1) DE69903458T2 (is)
DK (1) DK1115391T3 (is)
EA (1) EA200100369A1 (is)
EE (1) EE200100187A (is)
ES (1) ES2185378T3 (is)
GE (1) GEP20043199B (is)
HK (1) HK1040190A1 (is)
HR (1) HRP20010225B1 (is)
HU (1) HUP0103640A3 (is)
ID (1) ID30046A (is)
IL (1) IL141951A0 (is)
IS (1) IS5888A (is)
NO (1) NO20011493L (is)
NZ (1) NZ510504A (is)
OA (1) OA11659A (is)
PL (1) PL348673A1 (is)
PT (1) PT1115391E (is)
SK (1) SK3602001A3 (is)
TR (1) TR200100859T2 (is)
WO (1) WO2000018393A1 (is)
YU (1) YU22401A (is)
ZA (1) ZA200102233B (is)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1115391E (pt) * 1998-09-25 2003-02-28 Warner Lambert Co Quimioterapia do cancro com acetildinalina em combinacao com gemcitabina capecitabina ou cisplatina
CZ20022216A3 (cs) * 2001-07-02 2003-05-14 Warner-Lambert Company Kombinační chemoterapie
US20080075762A1 (en) * 2001-10-03 2008-03-27 Paul Tardi Compositions for delivery of drug combinations
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
US7456219B2 (en) * 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
MXPA04008577A (es) * 2002-03-04 2005-07-13 Aton Pharma Inc Metodos para inducir diferenciacion terminal.
JP2005530734A (ja) * 2002-04-15 2005-10-13 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 癌の処置のための併用療法
US20070032422A1 (en) 2002-10-24 2007-02-08 Spectrum Pharmaceuticals, Inc. Methods, compositions and articles of manufacture for contributing to the treatment of cancers
US8026216B2 (en) 2002-10-24 2011-09-27 Spectrum Pharmaceuticals, Inc. Methods and compositions for contributing to the treatment of cancers
GB0226434D0 (en) * 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
EP1562601A1 (en) * 2002-11-15 2005-08-17 Warner-Lambert Company LLC Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer
RU2240117C1 (ru) * 2003-04-01 2004-11-20 Алтайский государственный медицинский университет Способ лечения больных с местнораспространенными формами плоскоклеточного рака с локализацией в области слизистой оболочки полости рта и ротового отдела глотки
EP1643971A2 (en) * 2003-05-22 2006-04-12 Neopharm, Inc. Liposomal formulations comprising a combination of two or more active agents
PE20050206A1 (es) * 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
CN100431606C (zh) * 2004-11-22 2008-11-12 山东蓝金生物工程有限公司 一种抗癌药物组合物
US7957507B2 (en) 2005-02-28 2011-06-07 Cadman Patrick F Method and apparatus for modulating a radiation beam
CN100443081C (zh) * 2005-04-05 2008-12-17 吴一心 木犀草素与一种铂类化疗药物联合用于制备抗肿瘤的药物
US8232535B2 (en) 2005-05-10 2012-07-31 Tomotherapy Incorporated System and method of treating a patient with radiation therapy
US7639854B2 (en) 2005-07-22 2009-12-29 Tomotherapy Incorporated Method and system for processing data relating to a radiation therapy treatment plan
JP5060476B2 (ja) 2005-07-22 2012-10-31 トモセラピー・インコーポレーテッド 放射線療法を受けている患者の呼吸位相を検出するシステムおよび方法
US7567694B2 (en) 2005-07-22 2009-07-28 Tomotherapy Incorporated Method of placing constraints on a deformation map and system for implementing same
US7839972B2 (en) 2005-07-22 2010-11-23 Tomotherapy Incorporated System and method of evaluating dose delivered by a radiation therapy system
US8442287B2 (en) 2005-07-22 2013-05-14 Tomotherapy Incorporated Method and system for evaluating quality assurance criteria in delivery of a treatment plan
US7574251B2 (en) 2005-07-22 2009-08-11 Tomotherapy Incorporated Method and system for adapting a radiation therapy treatment plan based on a biological model
CN101268474A (zh) 2005-07-22 2008-09-17 断层放疗公司 用于估算实施剂量的方法和系统
US7773788B2 (en) * 2005-07-22 2010-08-10 Tomotherapy Incorporated Method and system for evaluating quality assurance criteria in delivery of a treatment plan
WO2007014106A2 (en) 2005-07-22 2007-02-01 Tomotherapy Incorporated System and method of delivering radiation therapy to a moving region of interest
JP2009506800A (ja) 2005-07-22 2009-02-19 トモセラピー・インコーポレーテッド 線量デリバリを予測する方法およびシステム
WO2007014091A2 (en) 2005-07-22 2007-02-01 Tomotherapy Incorporated System and method of generating contour structures using a dose volume histogram
EP3175886B1 (en) 2005-07-23 2018-06-27 TomoTherapy, Inc. Radiation therapy imaging and delivery utilizing coordinated motion of gantry and couch
ES2541657T3 (es) 2006-08-31 2015-07-23 Spectrum Pharmaceuticals, Inc. Sensibilización de células tumorales a terapia de radiación a través de la administración de agonistas de endotelina
EP2236145B1 (en) * 2008-01-28 2014-05-14 NanoCarrier Co., Ltd. Pharmaceutical composition and combined agent
FR2937867B1 (fr) * 2008-11-03 2011-03-04 Biorebus Association pharmaceutique contenant l acide lipoique et l acide hydroxycitrique a titre de principes actifs.
TWI477508B (zh) 2009-04-06 2015-03-21 Otsuka Pharma Co Ltd 用以治療癌症之組成物及方法
WO2012003413A1 (en) * 2010-06-30 2012-01-05 The Broad Institute, Inc. Novel solid forms of tacedinaline
US8691875B2 (en) 2011-07-01 2014-04-08 Broad Institute, Inc. Solid forms of tacedinaline
US9308235B2 (en) 2012-05-09 2016-04-12 Spectrum Pharmaceuticals, Inc. Treatment of primary and metastatic carcinoma
EP2711009A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. Compounds for use in treating or preventing primary and metastatic breast and prostate cancer
EP2711008A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. N6,N6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer
EP2711007A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. 4-Aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer
CN105027227B (zh) 2013-02-26 2017-09-08 安科锐公司 电磁致动的多叶准直器
US10189797B2 (en) * 2015-12-30 2019-01-29 Duke University Chemical modulators of immune checkpoints and therapeutic use
US11987579B2 (en) 2018-07-30 2024-05-21 Duke University Niclosamide analogues and therapeutic use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5562925A (en) * 1970-04-20 1996-10-08 Research Corporation Tech. Inc. Anti-tumor method
NZ219974A (en) * 1986-04-22 1989-08-29 Goedecke Ag N-(2'-aminophenyl)-benzamide derivatives, process for their preparation and their use in the control of neoplastic diseases
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
AU6878198A (en) 1997-04-24 1998-11-13 Warner-Lambert Company Use of acetyldinaline for the manufacture of a medicament for the treatment of renal cell carcinoma
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
PT1115391E (pt) * 1998-09-25 2003-02-28 Warner Lambert Co Quimioterapia do cancro com acetildinalina em combinacao com gemcitabina capecitabina ou cisplatina

Also Published As

Publication number Publication date
EE200100187A (et) 2002-08-15
OA11659A (en) 2004-12-08
ATE225655T1 (de) 2002-10-15
US20030086965A1 (en) 2003-05-08
EP1115391B1 (en) 2002-10-09
DE69903458D1 (de) 2002-11-14
GEP20043199B (en) 2004-03-25
CN1319009A (zh) 2001-10-24
CA2342981A1 (en) 2000-04-06
DK1115391T3 (da) 2003-02-10
AP2001002109A0 (en) 2001-03-31
YU22401A (sh) 2004-03-12
NO20011493L (no) 2001-05-23
US20030170300A1 (en) 2003-09-11
AU762079B2 (en) 2003-06-19
ZA200102233B (en) 2002-06-18
PL348673A1 (en) 2002-06-03
AU5092199A (en) 2000-04-17
HUP0103640A3 (en) 2003-01-28
IL141951A0 (en) 2002-03-10
JP2002525320A (ja) 2002-08-13
NZ510504A (en) 2003-09-26
WO2000018393A1 (en) 2000-04-06
HUP0103640A2 (en) 2002-06-29
TR200100859T2 (tr) 2001-08-21
HRP20010225A2 (en) 2002-04-30
HRP20010225B1 (en) 2004-10-31
BR9913952A (pt) 2001-06-12
HK1040190A1 (zh) 2002-05-31
EA200100369A1 (ru) 2001-10-22
PT1115391E (pt) 2003-02-28
DE69903458T2 (de) 2003-07-10
KR20010075348A (ko) 2001-08-09
ID30046A (id) 2001-11-01
EP1115391A1 (en) 2001-07-18
SK3602001A3 (en) 2002-07-02
BG105470A (en) 2001-12-29
ES2185378T3 (es) 2003-04-16
NO20011493D0 (no) 2001-03-23
US6469058B1 (en) 2002-10-22
CZ2001905A3 (cs) 2001-08-15

Similar Documents

Publication Publication Date Title
ID30046A (id) Kemoterapi kanker dengan asetildinalina digabung dengan gemsitabina, kapestabina atau kisplatin
CU23049A3 (es) Dihidropirimidinas.
BR9913221B1 (pt) composiÇço catalisadora suportada de metaloceno.
TR199902372A3 (tr) Sulfanilsilanlar.
NO20013099L (no) Kombinasjonskjemoterapi
ID24876A (id) Senyawa-senyawa indola tersubstitusi-2,3 sebagai penghambat cox-2
BR9912037B1 (pt) composições organometálicas.
DE69906149D1 (de) 4,5-azolo-oxindole
DK1140890T3 (da) Chromanderivater.
NL1011999A1 (nl) Trisresorcinyltriazinen.
ES1044767Y (es) Grifo.
NL1008191A1 (nl) Afdichting.
BR9908946B1 (pt) forração.
IT1313300B1 (it) Apparecchio frigorifero.
DE59909590D1 (de) Azidfreie, gaserzeugende zusammensetzung
IT1303351B1 (it) Tavolo pensile.
ITTO980674A1 (it) Elicottero.
ES1041060Y (es) Cortapuros.
ES1041196Y (es) Junquillo mixto para estancaje de cristales.
ES1040731Y (es) Gafa.
ES1040343Y (es) Carrito portafregona.
ES1039730Y (es) Rodapie.
ES1042117Y (es) Mesa-sombrilla.
ES1040589Y (es) Expositor-dispensador.
ES1040633Y (es) Escalifono.